SCHEMBL4862897

SCHEMBL4862897

O=c1c([N+](=O)[O-])c(-c2cnn(-c3ccccc3)c2)n(Cc2ccccc2F)c(=O)n1Cc1ccccc1F

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.44
L3MBTL1 Q9Y468 2/20 0.43
HSP90AA1 P07900 1/20 0.43
LMNA P02545 2/20 0.39
ADORA2A P29274 2/20 0.39
ADORA2B P29275 2/20 0.39
ADORA1 P30542 2/20 0.39
TP53 P04637 2/20 0.38
GAA P10253 1/20 0.38
TSHR P16473 2/20 0.37
MAPT P10636 1/20 0.37
NPC1 O15118 1/20 0.37
KDM4E B2RXH2 1/20 0.37
MAPK1 P28482 1/20 0.37
HTT P42858 1/20 0.37
HSD17B10 Q99714 1/20 0.37
CYP1A2 P05177 1/20 0.36
CYP2C19 P33261 1/20 0.36
PKM P14618 1/20 0.35
PKLR P30613 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4867853 0.90 MAPT (0.42) ALDH1A1HSP90AA1TP53MAPTKDM4E
SCHEMBL4864902 0.87 ADORA2B (0.49) ALDH1A1L3MBTL1LMNAADORA2AADORA2B
SCHEMBL4866426 0.86 ALDH1A1 (0.46) ALDH1A1L3MBTL1LMNAADORA2AADORA2B
SCHEMBL4864054 0.83 HSP90AA1 (0.43) ALDH1A1HSP90AA1LMNAADORA2AADORA2B
SCHEMBL4863501 0.82 HSP90AA1 (0.46) ALDH1A1HSP90AA1LMNAADORA2AADORA2B
SCHEMBL4769545 0.82 NPC1 (0.39) ALDH1A1L3MBTL1HSP90AA1LMNATP53
SCHEMBL4859903 0.82 HSP90AA1 (0.44) ALDH1A1L3MBTL1HSP90AA1ADORA2AADORA2B
SCHEMBL4866000 0.81 HSP90AA1 (0.47) ALDH1A1HSP90AA1LMNAADORA2AADORA2B
SCHEMBL4859065 0.80 HSP90AA1 (0.41) ALDH1A1HSP90AA1LMNAADORA2AADORA2B
SCHEMBL4858904 0.80 ADORA2B (0.48) ALDH1A1L3MBTL1LMNAADORA2AADORA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7449473-B2 Substituted pyrrolo[3,2-d]pyrimidin-2,4-diones as A2b adenosine receptor antagonists CV THERAPEUTICS, INC. (US) 2008-11-11 US disclosed
EP-1678181-A2 A2B ADENOSINE RECEPTOR ANTAGONISTS CV THERAPEUTICS, INC. (US) 2006-07-12 EP disclosed
US-20050119287-A1 A2B adenosine receptor antagonists GILEAD PALO ALTO, INC. 2005-06-02 US disclosed
WO-2005042534-A2 A2B ADENOSINE RECEPTOR ANTAGONISTS CV THERAPEUTICS, INC. (US) 2005-05-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050119287-A1 A2B adenosine receptor antagonists ADORA2B, ADORA2A, ADORA3 ALDH1A1 1178/4885L3MBTL1 2622/4885HSP90AA1 1863/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.